Table 6.
Analysis of interaction between selected SNPsa and platinum chemotherapy treatment.
| All-cause death |
Cancer death |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Did not receive platinum chemotherapy |
Received platinum chemotherapy |
Did not receive platinum chemotherapy |
Received platinum chemotherapy |
||||||
| Gene | SNP | # Died/# survived/ missing |
Adjusted HR (95% CI)b |
# Died/# survived/ missing |
Adjusted HR (95% CI)b |
# Died/# survived/ missing |
Adjusted HR (95% CI)c |
# Died/# survived/ missing |
Adjusted HR (95% CI)c |
| CYP2E1 | rs3813865 | ||||||||
| GG | 295/398 | 1.00 (ref) | 180/229 | 0.67 (0.51–0.87) | 114/579 | 1.00 (ref) | 81/328 | 0.55 (0.35–0.86) | |
| GC + CC | 37/33 | 1.40 (0.97–2.02) | 33/22 | 0.92 (0.61–1.40) | 18/52 | 2.34 (1.30–4.23) | 14/41 | 1.13 (0.58–2.20) | |
| rs8192772 | |||||||||
| TT | 270/378 | 1.00 (ref) | 167/211 | 0.67 (0.50–0.88) | 101/547 | 1.00 (ref) | 77/301 | 0.64 (0.40–1.01) | |
| TC + CC | 61/53 | 1.50 (1.11–2.01) | 46/40 | 0.88 (0.61–1.29) | 31/83 | 2.34 (1.50–3.66) | 18/68 | 0.80 (0.43–1.50) | |
| rs7092584 | |||||||||
| CC | 256/352 | 1.00 (ref) | 155/199 | 0.66 (0.49–0.87) | 96/512 | 1.00 (ref) | 73/281 | 0.61 (0.38–0.97) | |
| CT + TT | 74/79 | 1.22 (0.92–1.60) | 58/52 | 0.83 (0.58–1.18) | 35/118 | 1.44 (0.93–2.24) | 22/88 | 0.70 (0.39–1.26) | |
| rs743535 | |||||||||
| CC | 251/356 | 1.00 (ref) | 164/198 | 0.70 (0.53–0.93) | 94/513 | 1.00 (ref) | 73/289 | 0.61 (0.39–0.98) | |
| CT + TT | 79/72 | 1.34 (1.02–1.77) | 47/51 | 0.72 (0.49–1.05) | 37/114 | 1.62 (1.04–2.52) | 21/77 | 0.66 (0.35–1.23) | |
| rs2249695 | |||||||||
| CC | 161/239 | 1.00 (ref) | 85/138 | 0.58 (0.41–0.82) | 60/340 | 1.00 (ref) | 41/182 | 0.50 (0.28–0.88) | |
| CT + TT | 171/192 | 1.01 (0.79–1.28) | 128/112 | 0.77 (0.56–1.06) | 72/291 | 1.30 (0.84–2.00) | 54/186 | 0.80 (0.47–1.36) | |
| GPx2 | rs11623705 | ||||||||
| GG | 268/347 | 1.00 (ref) | 185/200 | 0.70 (0.53–0.91) | 96/519 | 1.00 (ref) | 77/308 | 0.62 (0.40–0.97) | |
| GT + TT | 64/84 | 0.99 (0.73–1.34) | 28/51 | 0.54 (0.34–0.85) | 36/112 | 1.63 (1.02–2.61) | 18/61 | 0.70 (0.36–1.37) | |
| rs2412065 | |||||||||
| GG | 172/252 | 1.00 (ref) | 122/152 | 0.69 (0.51–0.93) | 59/365 | 1.00 (ref) | 56/218 | 0.72 (0.43–1.20) | |
| GC + CC | 160/179 | 1.03 (0.82–1.31) | 91/99 | 0.68 (0.49–0.95) | 73/266 | 1.55 (1.03–2.33) | 39/151 | 0.68 (0.39–1.19) | |
| SOD1 | rs10432782 | ||||||||
| TT | 227/318 | 1.00 (ref) | 144/187 | 0.69 (0.52–0.92) | 89/456 | 1.00 (ref) | 63/268 | 0.53 (0.33–0.86) | |
| TG + GG | 105/113 | 1.19 (0.92–1.53) | 69/63 | 0.74 (0.53–1.04) | 43/175 | 1.16 (0.76–1.78) | 32/100 | 0.72 (0.42–1.24) | |
| rs2070424 | |||||||||
| AA | 267/365 | 1.00 (ref) | 161/212 | 0.66 (0.50–0.86) | 105/527 | 1.00 (ref) | 70/303 | 0.52 (0.33–0.82) | |
| AG + GG | 65/66 | 1.08 (0.80–1.46) | 52/39 | 0.77 (0.54–1.11) | 27/104 | 0.96 (0.57–1.63) | 25/66 | 0.73 (0.41–1.29) | |
| SOD2 | rs2842980 | ||||||||
| AA | 178/266 | 1.00 (ref) | 121/152 | 0.67 (0.49–0.90) | 67/377 | 1.00 (ref) | 46/227 | 0.49 (0.29–0.82) | |
| AT + TT | 154/165 | 1.06 (0.84–1.34) | 92/99 | 0.73 (0.53–1.01) | 65/254 | 1.23 (0.83–1.84) | 49/142 | 0.85 (0.50–1.44) | |
SNPs were selected for presentation in this table if the confidence interval for the adjusted HR and the Kaplan–Meier log-rank p-value both appeared to depart from the null, for either all-cause or cancer-specific death, or both.
Cox models used to calculate hazard ratios for all-cause death included SNP coded for dominant model (any minor allele versus homozygous major allele), anatomical site, T stage, N stage, M stage, angiolymphatic invasion status, treatment (surgery), presence of comorbid cardiovascular or lung disease, duration of smoking cigarettes (years), reception of at least one routine dental visit in past 10 years. 25 datasets were imputed, and results were summarized as a single HR.
Cox models used to calculate hazard ratios for cancer-specific death included SNP coded for dominant model (any minor allele versus homozygous major allele) and all covariates listed above for all-cause death models, plus the following additional variables: radiation treatment, presence of comorbid liver disease or hepatitis, sex, race, age, federal poverty level, ever exposure to environmental tobacco smoke at work, ever loss of a tooth due to disease. 25 datasets were imputed, and results were summarized as a single HR.